. . "Epitopoietic Research Corporation"@en . . . "2006"^^ . . . . . . . . . "February 2021"@en . . "Thomas Chen"@en . . . . . . "2006"^^ . . . . . . . . . . "Vince Dell"@en . "64559199"^^ . "Epitopoietic Research Corporation (ERC) is a Belgian Pharmaceutical company developing ERC1671 (brandnames: Gliovac, Sitoiganap (EU)), which specialise in treatment for Glioblastoma multiforme which is the most aggressive form of brain cancer. In 2019, ERC became the first pharmaceutical company to provide treatment under the US Federal Right-to-try law."@en . . . . . . . . "Epitopoietic Research Corporation"@en . "the dark area at lower left quadrant, or the darkish area with white border straddling the upper/lower right quadrant, or maybe it is something else"@en . . . . . . . "19315"^^ . . . . . . "1120863670"^^ . . . . . . . . . . . . "Epitopoietic Research Corporation (ERC) is a Belgian Pharmaceutical company developing ERC1671 (brandnames: Gliovac, Sitoiganap (EU)), which specialise in treatment for Glioblastoma multiforme which is the most aggressive form of brain cancer. In 2019, ERC became the first pharmaceutical company to provide treatment under the US Federal Right-to-try law."@en . . . . "Apostolos Stathopoulos"@en . . . . . . . "ERC1671"@en . . . . . "Epitopoietic Research Corporation"@en . . . . "Virgil Schijns Joseph Elliot"@en . . . . "File:Erc_Immunotherapy_logo.png"@en . .